Collection of Tissue Blocks or Slides From Patients With Cancer
| Status: | Recruiting |
|---|---|
| Conditions: | Cancer, Cancer, Cancer, Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 18 - 99 |
| Updated: | 3/14/2019 |
| Start Date: | June 10, 2011 |
| End Date: | January 1, 2023 |
| Contact: | Paula A Carter, R.N. |
| Email: | pcartera@mail.nih.gov |
| Phone: | (240) 858-3191 |
BACKGROUND:
Cancer of any type is a serious disease and despite all the progress made from past research,
there is still much that is poorly understood at the molecular level. Recent advances in
biomedical technology platforms have emerged as critical tools for accelerating personalized
medicine. The collection of human tissue specimens has been an invaluable resource for
conducting translational cancer research using these developing technologies. The ultimate
goal is to understand the molecular indicators of cancer development and progression. While
it is ideal to be able to study clinical samples, specifically tissue biopsies, they are
however precious and are often difficult to obtain in sufficient quantities or numbers to
conduct proteomic or molecular profiling studies. There exists, however, a vast archive of
pathologically characterized clinical samples in the form of formalin-fixed paraffin-embedded
tissue blocks. The preservation of these tissue blocks and/or slides for long-term (years)
storage is an important asset that aids in translational and clinical research. This protocol
will describe the procedures for receiving, labeling and storing paraffin-embedded tissue
blocks and/or slides until they are needed for future analysis. When blocks are ready for
analysis, the requestor will then follow the IRB protocol specific to that study.
OBJECTIVE:
- To obtain tissue blocks and slides from outside pathology departments for cancer patients
being treated at the Medical Oncology Branch (MOB) and Affiliates Center for Cancer Research
(CCR), National Cancer Institute (NCI) in order to store them for future studies and analysis
(e.g., using molecular technology platforms).
ELIGIBILITY:
- Patients suspected of having, or with biopsy proof of malignant disease will be evaluated
in the Medical Oncology Branch and Affiliates Clinics, NCI.
DESIGN:
- Tissue blocks and slides will be acquired from outside pathology departments and
received by the Clinical Pharmacology Program of the MOB/CCR/NCI for coding.
- Bar-coded tissue blocks and slides will then be transferred to the Laboratory of
Pathology/CCR/NCI for proper long-term storage.
Cancer of any type is a serious disease and despite all the progress made from past research,
there is still much that is poorly understood at the molecular level. Recent advances in
biomedical technology platforms have emerged as critical tools for accelerating personalized
medicine. The collection of human tissue specimens has been an invaluable resource for
conducting translational cancer research using these developing technologies. The ultimate
goal is to understand the molecular indicators of cancer development and progression. While
it is ideal to be able to study clinical samples, specifically tissue biopsies, they are
however precious and are often difficult to obtain in sufficient quantities or numbers to
conduct proteomic or molecular profiling studies. There exists, however, a vast archive of
pathologically characterized clinical samples in the form of formalin-fixed paraffin-embedded
tissue blocks. The preservation of these tissue blocks and/or slides for long-term (years)
storage is an important asset that aids in translational and clinical research. This protocol
will describe the procedures for receiving, labeling and storing paraffin-embedded tissue
blocks and/or slides until they are needed for future analysis. When blocks are ready for
analysis, the requestor will then follow the IRB protocol specific to that study.
OBJECTIVE:
- To obtain tissue blocks and slides from outside pathology departments for cancer patients
being treated at the Medical Oncology Branch (MOB) and Affiliates Center for Cancer Research
(CCR), National Cancer Institute (NCI) in order to store them for future studies and analysis
(e.g., using molecular technology platforms).
ELIGIBILITY:
- Patients suspected of having, or with biopsy proof of malignant disease will be evaluated
in the Medical Oncology Branch and Affiliates Clinics, NCI.
DESIGN:
- Tissue blocks and slides will be acquired from outside pathology departments and
received by the Clinical Pharmacology Program of the MOB/CCR/NCI for coding.
- Bar-coded tissue blocks and slides will then be transferred to the Laboratory of
Pathology/CCR/NCI for proper long-term storage.
Background
- Cancer of any type is a serious disease and despite all the progress made from past
research, there is still much that is poorly understood at the molecular level.
- Recent advances in biomedical technology platforms have emerged as critical tools for
accelerating personalized medicine.
- The collection of human tissue specimens has been an invaluable resource for conducting
translational cancer research using these developing technologies.
- The ultimate goal is to understand the molecular indicators of cancer development and
progression.
- While it is ideal to be able to study clinical samples, specifically tissue biopsies,
they are however precious and are often difficult to obtain in sufficient quantities or
numbers to conduct proteomic or molecular profiling studies.
- There exists, however, a vast archive of pathologically characterized clinical samples
in the form of formalin-fixed paraffin-embedded tissue blocks.
- The preservation of these tissue blocks and/or slides for long-term (years) storage is
an important asset that aids in translational and clinical research.
- This protocol will describe the procedures for receiving, labeling and storing
paraffinembedded tissue blocks and/or slides until they are needed for future analysis.
- When blocks are ready for analysis, the requestor will then follow the IRB protocol
specific to that study.
Objective
-To obtain tissue blocks and slides from outside pathology departments for cancer patients
being treated at the Genitourinary Malignancies Branch (GMB) and Affiliates Center for Cancer
Research (CCR), National Cancer Institute (NCI) in order to store them for future studies and
analysis (e.g., using molecular technology platforms).
Eligibility
-Patients suspected of having, or with biopsy proof of malignant disease will be evaluated in
the Genitourinary Malignancies Branch (GMB) and Affiliates Clinics, NCI.
Design
- This protocol is not a research study.
- Tissue blocks and slides will be acquired from outside pathology departments and
received by the Clinical Pharmacology Program of the OCD/CCR/NCI for coding.
- Bar-coded tissue blocks and slides will then be transferred to the Laboratory of
Pathology/CCR/NCI for proper long-term storage.
- Cancer of any type is a serious disease and despite all the progress made from past
research, there is still much that is poorly understood at the molecular level.
- Recent advances in biomedical technology platforms have emerged as critical tools for
accelerating personalized medicine.
- The collection of human tissue specimens has been an invaluable resource for conducting
translational cancer research using these developing technologies.
- The ultimate goal is to understand the molecular indicators of cancer development and
progression.
- While it is ideal to be able to study clinical samples, specifically tissue biopsies,
they are however precious and are often difficult to obtain in sufficient quantities or
numbers to conduct proteomic or molecular profiling studies.
- There exists, however, a vast archive of pathologically characterized clinical samples
in the form of formalin-fixed paraffin-embedded tissue blocks.
- The preservation of these tissue blocks and/or slides for long-term (years) storage is
an important asset that aids in translational and clinical research.
- This protocol will describe the procedures for receiving, labeling and storing
paraffinembedded tissue blocks and/or slides until they are needed for future analysis.
- When blocks are ready for analysis, the requestor will then follow the IRB protocol
specific to that study.
Objective
-To obtain tissue blocks and slides from outside pathology departments for cancer patients
being treated at the Genitourinary Malignancies Branch (GMB) and Affiliates Center for Cancer
Research (CCR), National Cancer Institute (NCI) in order to store them for future studies and
analysis (e.g., using molecular technology platforms).
Eligibility
-Patients suspected of having, or with biopsy proof of malignant disease will be evaluated in
the Genitourinary Malignancies Branch (GMB) and Affiliates Clinics, NCI.
Design
- This protocol is not a research study.
- Tissue blocks and slides will be acquired from outside pathology departments and
received by the Clinical Pharmacology Program of the OCD/CCR/NCI for coding.
- Bar-coded tissue blocks and slides will then be transferred to the Laboratory of
Pathology/CCR/NCI for proper long-term storage.
- INCLUSION CRITERIA:
- Any cancer patient who is being evaluated at the National Cancer Institute with
available tissue samples (blocks or slides) is eligible
- Must be able and willing to sign an informed consent for this study
- Age: greater than or equal to 18 years of age
EXCLUSION CRITERIA:
We found this trial at
1
site
9000 Rockville Pike
Bethesda, Maryland 20892
Bethesda, Maryland 20892
Click here to add this to my saved trials
